Lung Cancer Clinical Trial

Vinorelbine Tartrate and Paclitaxel in Treating Older Patients With Advanced Non-Small Cell Lung Cancer

Summary

This phase II trial studies the side effects and how well vinorelbine tartrate and paclitaxel works in treating older patients with non-small cell lung cancer that has spread to other placed in the body. Drugs used in chemotherapy, such as vinorelbine tartrate and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving combination chemotherapy may kill more tumor cells.

View Full Description

Full Description

PRIMARY OBJECTIVES: I. To assess the safety and efficacy of a combination of vinorelbine and paclitaxel administered weekly to elderly patients with advanced non-small cell lung cancer. II. To assess the response rate of a combination of vinorelbine and paclitaxel administered weekly to elderly patients with advanced non-small cell lung cancer. III. To assess the quality of life of elderly patients with advanced non-small cell lung cancer during administration of weekly paclitaxel and vinorelbine. OUTLINE: Patients receive vinorelbine tartrate intravenously (IV) over 6-10 minutes and paclitaxel IV over 1 hour once weekly for 6 weeks. Treatment repeats every 8 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 5 years.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Pathologically proven non-small cell lung cancer with evidence of distant metastases/malignant pleural effusion
Measurable disease on imaging studies in 2 dimensions
No previous therapy with either paclitaxel or vinorelbine, or any chemotherapy for the past five years
Patients who have had a previous resection for their lung cancer and present with recurrent disease will be eligible
Patients with other prior malignancies will be included, provided they have been disease-free for at least five years
Patients with adequately treated basal cell or squamous cell carcinoma of the skin, adequately treated carcinoma in-situ of the cervix and hormone sensitive prostate cancer will be eligible
Karnofsky score >= 70 (Eastern Cooperative Oncology Group [ECOG] 0-2)
White blood cell (WBC) count >= 3,500/mm^3, OR
Absolute neutrophil count (ANC) >= 1,500/ul
Platelet count >= 100,000/mm^3
Serum creatinine less than 1.5 times the upper limits of normal
Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than 1.5 times the upper limits of normal
Serum alkaline phosphatase less than 2.5 times the upper limits of normal
No active serious infections or other condition precluding chemotherapy
Non-pregnant and non-nursing
Men and women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method while on the study
Able to give informed consent
Able to return for treatment and follow-up as specified in the protocol

Exclusion Criteria:

Known hypersensitivity to any component of vinorelbine or paclitaxel or other required drugs in the study
Any comorbidity or condition which, in the opinion of the investigator, may interfere with the assessments and procedures of this protocol
Inability to fulfill the requirements of the protocol

Study is for people with:

Lung Cancer

Phase:

Phase 2

Estimated Enrollment:

20

Study ID:

NCT00602797

Recruitment Status:

Completed

Sponsor:

University of Nebraska

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 5 Locations for this study

See Locations Near You

CHI Health Saint Francis
Grand Island Nebraska, 68803, United States
Great Plains Regional Medical Center
North Platte Nebraska, 69103, United States
Veterans Administration Medical Center, Omaha
Omaha Nebraska, 68105, United States
University of Nebraska Medical Center
Omaha Nebraska, 68198, United States
Avera McKennan Hospital and University Health Center
Sioux Falls South Dakota, 57105, United States

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Phase:

Phase 2

Estimated Enrollment:

20

Study ID:

NCT00602797

Recruitment Status:

Completed

Sponsor:


University of Nebraska

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.